Ahmet Sezer

机构：Başkent University · ORCID：0009-0005-0183-5573

发表论文 76 篇 · 总被引 594 次 · h-index 13

代表论文

• Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial (2023 · Journal of Thoracic Oncology · 被引 23)
• Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy (2024 · Journal of the American Society of Echocardiography · 被引 21)
• Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study (2023 · Journal of Thoracic Oncology · 被引 19)
• Consensus statement addressing controversies and guidelines on pediatric urolithiasis (2024 · World Journal of Urology · 被引 15)
• The burden of major complications on failure to rescue after surgery for acute type A aortic dissection: Analysis of more than 19,000 patients (2024 · Journal of Thoracic and Cardiovascular Surgery · 被引 10)
• Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50% (2025 · Cancer · 被引 8)